Oruka Therapeutics Inc (ORKA) Institutional Holdings & 13F Data (Q2 2026)

ORKA ranks #2398 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ORKA is a top-conviction position for Remedium Capital Partners, LLC — at 33.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ORKA belongs to FMR LLC, but the position matters far more to Remedium Capital Partners, LLC, who has 33.0% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its ORKA position for two straight quarters, increasing it by $641.9M to reach $862.0M today.

Sterling Capital Management LLC has trimmed its ORKA position for two straight quarters, cutting it by $50.6K while still holding $16.8K.

ORKA is down 2.9% today, but institutions show net buying of $2.4B this quarter — a divergence between today's price move and the underlying institutional flow.

ORKA reported a net loss of $132.9M over the trailing twelve months.

• Not yet profitable — net loss of $132.9M over the trailing twelve months
• Net income declined year over year, from -$96.4M to -$132.9M
• Operating cash flow was negative, using $88.2M in cash
• Current ratio of 22.37x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.04x equity — within a conventional range